Objective To investigate the effect of specialized standardized follow-up manual for postoperative patients with papillillary thyroid microcarcinoma (PTMC). Methods A total of 200 PTMC patients were randomly divided into study group and control group each 100 cases. Both groups received specialized health education during hospitalization. The patients in study group got specialized follow-up after discharge using the standardized manual of follow-up. Thyroid stimulating hormone (TSH) should be suppressed to 0.1 mU/L for patients with PTMC in both groups postoperatively. Contents of detailed specialized follow-up included diet, medical treatment and exercise. Outcome of follow-up was compared between 2 groups for TSH detection and neck ultrasound examination. Compliance rate was involved low-iodine diet, Euthyrox medication and exercise. Results No recurrent PTMC was found 3 months later postoperatively with ultrasound examination for both groups. Values of TSH in study group were significantly lower than those in control group after 1 month of operation (P< 0.05). There was statistical significant difference in regular follow-up rate, adherent rate of low iodine diet, Euthyrox medication and exercise between 2 groups (P< 0.05). Conclusions The application of specialized follow-up manual in postoperative patients is helpful to improve compliance for treatment and the effect of TSH inhibition.
GUO Ying, ZHENG Lei, ZHANG Shiyu, YANG Weiping, YAN Jieqi, KUANG Jie, CHEN Xi
. Specialized clinical follow-up of patients with papillary thyroid microcarcinoma after radical resection[J]. Journal of Surgery Concepts & Practice, 2019
, 24(03)
: 254
-258
.
DOI: 10.16139/j.1007-9610.2019.03.016
[1] Nixon IJ, Wang LY, Migliacci JC, et al.An international multi-institutional validation of age 55 years as a cutoff for risk stratification in the AJCC/UICC staging system for well-differentiated thyroid cancer[J]. Thyroid,2016,26(3):373-380.
[2] Tuttle RM, Haugen B, Perrier ND.Updated American Joint Committee on Cancer/tumor-node-metastasis staging system for differentiated and anaplastic thyroid cancer(eighth edition): what changed and why?[J]. Thyroid,2017,27(6):751-756.
[3] Morisky DE, Green LW, Levine DM.Concurrent and predictive validity of a self-reported measure of medication adherence[J]. Med Care,1986,24(1):67-74.
[4] 吴凡, 赵金霞, 王天晟, 等. 中文版MMAS-8测量类风湿关节炎患者用药依从性的信效度分析[J]. 中国药房,2018,29(2):263-267.
[5] 中华医学会内分泌学分会, 中华医学会外科学分会内分泌学组, 中国抗癌协会头颈肿瘤专业委员会,等. 甲状腺结节和分化型甲状腺癌诊治指南[J]. 中国肿瘤临床,2012,39(17):1249-1272.
[6] 陈万青, 孙可欣, 郑荣寿, 等. 2014年中国恶性肿瘤发病和死亡分析[J]. 中华肿瘤杂志,2018,27(1):5-13.
[7] 刘静思, 廖泉. 甲状腺微小乳头状癌诊治进展[J]. 中国实用外科杂志,2017,37(5):588-590.
[8] Hundahl SA, Fleming ID, Fremgen AM, et al.A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995[J]. Cancer,1998, 83(12):2638-2648.
[9] American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer[J]. Thyroid,2009,19(11):1167-1214.
[10] Neimeier LA, Akatsu HK, Song C, et al.A combined molecular-pathologic score improves risk stratification of papillary microcarcinoma[J]. Cancer,2012,118(8):2069-2077.
[11] 刘晓莉, 孙辉. 甲状腺乳头状微小癌的术后管理及动态风险评估[J]. 中华内分泌外科杂志,2016,10(4):265-268.
[12] 田文, 郗洪庆, 王冰, 等. 重视甲状腺癌术后规范化长期随访[J]. 中国实用外科杂志,2017,137(9):937-940.
[13] 中国抗癌协会甲状腺癌专业委员会. 甲状腺微小乳头状癌诊断与治疗中国专家共识(2016版)[J]. 中国肿瘤临床,2016,43(10):405-411.
[14] Duner A.Care planning and decision making in teams in Swedish elderly care: a study of interprofessional collabo-ration and professional boundaries[J]. J Inter Prof Care,2013,27(3):246-253.
[15] 陈曦. 大数据时代甲状腺癌诊治思考[J]. 中国实用外科杂志,2016,36(5):494-497.
[16] Mooney SJ, Westreich DJ, El-Sayed AM.Commentary: Epidemiologyin the era of big data[J]. Epidemiology,2015,26(3):390-394
[17] Haugen BR, Alexander EK, Bible KC,et al.2015 Ameri-can Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroidcancer: The American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer[J]. Thyroid,2016,26(1):1-133.
